Tuberous Sclerosis Complex

Status: draft · Last updated 2026-11-17 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Autosomal dominant; two thirds de novo.
    • TSC1/TSC2 loss causes mTORC1 overactivity.
    • A pathogenic variant alone is diagnostic. Mosaicism is possible .
  • Diagnosis: 2 major features, or 1 major plus 2 or more minor .
  • Brain causes the most morbidity; kidney causes the most deaths .
  • The brain trio: tubers 82%, subependymal nodules 78%, SEGA about 25% (more with TSC2) .
  • Epilepsy in 70–90%. Screen infants with EEG .
  • Rhabdomyomas: a prenatal clue that regresses .
  • Angiomyolipomas:
    • an mTOR inhibitor if over 4 cm (or rapidly growing and over 3 cm);
    • embolization plus steroids for bleeding;
    • avoid nephrectomy .
  • LAM in adult women: sirolimus stabilizes FEV1. Avoid estrogen and smoking .
  • Workup at diagnosis: genetics, brain MRI and EEG, TAND screen, eye examination, echocardiogram and ECG, abdominal MRI with BP and GFR, chest CT in adult women, skin and dental examination .

Landmark papers

  • Updated international TSC criteria (Northrup et al., Pediatr Neurol 2021): definite TSC is 2 major features, or 1 major plus 2 or more minor features, or a pathogenic variant. The 2021 update made only two changes to the clinical criteria .
  • EXIST-2 (Bissler et al., Lancet 2013): a randomized, placebo-controlled trial in 118 adults with angiomyolipomas of 3 cm or more. A 50% or greater volume reduction occurred in 42% with everolimus vs 0% with placebo .
  • MILES (McCormack et al., N Engl J Med 2011): sirolimus in 89 patients with lymphangioleiomyomatosis and moderate impairment stabilized FEV1 (+1 vs −12 mL per month on placebo), and the decline resumed after stopping .

Tuberous sclerosis complex (TSC) is inherited in an autosomal dominant pattern. It affects many organ systems and varies widely in presentation .

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:tuberous_sclerosis:e78b5fba97205d88© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Coronal brain through the foramina of Monro with cortical tubers, radial migration lines, calcified subependymal nodules along the caudothalamic groove and a SEGA obstructing the foramen; the mTOR pathway with TSC1-TSC2 inhibiting Rheb and mTORC1 blocked by everolimus or sirolimus; and facial angiofibromas, an ash-leaf macule, a shagreen patch, cardiac rhabdomyomas and renal angiomyolipomas(A) BRAIN: TUBERS, SUBEPENDYMAL NODULES AND SEGA (CORONAL THROUGH THE FORAMINA OF MONRO)cortical tuber: expandedgyrus, blurred grey-whitejunctionradial migration lineSEGA at the foramen ofMonro (enlarging,enhancing)obstructed ventricletubertubercalcified subependymalnodules along thecaudothalamic groovethalamostriate veintuber(B) mTOR PATHWAYgrowth factors,insulin, nutrientsPI3K - AKTTSC1 - TSC2hamartin - tuberinRheb-GTPmTORC1cell growth,proliferation (S6K, 4E-BP1)loss-of-function mutation in TSC1 or TSC2 (TSC2 more severe)releases Rheb, so mTORC1 is constitutively activeeverolimus /sirolimus (+ FKBP12)(C) SYSTEMIC FEATURESfacial angiofibromasmalar, nasolabialhypomelanotic macules"ash-leaf", 3 or moreshagreen patchlumbosacral, orange-peelcardiac rhabdomyomafetal / neonatal; regressrenal angiomyolipomafat-containing; bleeding risk
Tuberous sclerosis complex. (a) Brain: cortical tubers, radial migration lines, subependymal nodules along the caudothalamic groove, and a SEGA at the foramen of Monro. (b) mTOR pathway: TSC1–TSC2 complex inhibits Rheb–mTORC1; loss of either gene releases cell growth, and everolimus or sirolimus blocks mTORC1. (c) Systemic findings: facial angiofibromas, hypomelanotic macules, shagreen patch, cardiac rhabdomyoma, renal angiomyolipoma. Not to scale.

Genetics

Clinical diagnosis (2021 international criteria)

Organ systems

Brain and behavior

Skin and mouth

Eye

Heart

Kidney: the leading cause of death

Lung

Other organs

Workup at diagnosis

Based on the international recommendations and GeneReviews ; see caveats.

Ongoing surveillance (GeneReviews)

Where mTOR inhibitors fit

Related topics

References

  1. Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011. PMID 34399110. verified
  2. Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous sclerosis complex. In: Adam MP, et al., eds. GeneReviews. Seattle (WA): University of Washington, Seattle; 1999 (updated 2024). PMID 20301399. verified
  3. Kingswood JC, d'Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA): baseline data on 2093 patients. Orphanet J Rare Dis 2017;12(1):2. doi:10.1186/s13023-016-0553-5. PMID 28057044. verified
  4. Jansen AC, Belousova E, Benedik MP, et al. Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex. Front Neurol 2019;10:705. doi:10.3389/fneur.2019.00705. PMID 31333563. verified
  5. Farach LS, Richard MA, Wulsin AC, et al. Drug-resistant epilepsy in tuberous sclerosis complex is associated with TSC2 genotype: more findings from the Preventing Epilepsy Using Vigabatrin (PREVeNT) trial. Pediatr Neurol 2024;159:62–71. doi:10.1016/j.pediatrneurol.2024.06.012. PMID 39142021. verified
  6. Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol 2021;89(2):304–314. doi:10.1002/ana.25956. PMID 33180985. verified
  7. Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA Dermatol 2018;154(7):773–780. doi:10.1001/jamadermatol.2018.0464. PMID 29800048. verified
  8. Öhnell HM, Kjellström U, Eklund E, et al. Ophthalmic manifestations in children with tuberous sclerosis complex. Acta Ophthalmol 2024;102(4):421–427. doi:10.1111/aos.15812. PMID 37991117. verified
  9. Craig K, Patel J, Murphy D, et al. Paediatric cardiac tumours: a national population study. Pediatr Cardiol 2026;47(3):1200–1208. doi:10.1007/s00246-025-03893-7. PMID 40366416. verified
  10. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817–824. doi:10.1016/S0140-6736(12)61767-X61767-X). PMID 23312829. verified
  11. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364(17):1595–1606. doi:10.1056/NEJMoa1100391. PMID 21410393. verified
  12. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125–132. doi:10.1016/S0140-6736(12)61134-961134-9). PMID 23158522. verified
  13. French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016;388(10056):2153–2163. doi:10.1016/S0140-6736(16)31419-231419-2). PMID 27613521. verified
  14. Tran LH, Zupanc ML. Long-term everolimus treatment in individuals with tuberous sclerosis complex: a review of the current literature. Pediatr Neurol 2015;53(1):23–30. doi:10.1016/j.pediatrneurol.2014.10.024. PMID 26092412. verified

Verification (2026-11-17):

Caveats: